KOSDAQBiotech & Pharma291650

Aptamer Sciences

₩2,160▼ 0.92%2026-11-18 close
Market Cap
₩65.9B
Turnover
₩17,565,655
Volume
8.3K
Shares out.
30.5M
PER
—
PBR
1.6×
EPS
-₩395
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Is Growing, but Losses Persist

CHOOLIP & SCIENCES posted third-quarter 2026 revenue of KRW 3.64 billion, the largest of the last five quarters, yet operating and net losses have continued for five straight quarters since the third quarter of 2025.

  1. 1

    Annual revenue rose from KRW 358 million in 2022 to KRW 3.5 billion in 2025, increasing in both 2024 and 2025.

  2. 2

    Third-quarter 2026 revenue of KRW 3.64 billion rose 568.5% year on year and has grown for two straight quarters since the first quarter of 2026.

  3. 3

    The operating loss narrowed to KRW 1.59 billion in the third quarter of 2026, after widening to KRW 3.08 billion in the second quarter, so quarterly swings remain large.

  4. 4

    Attributable net losses for the last four quarters total KRW 11.3 billion, and at the end of 2025 total equity stood at KRW 28.2 billion against total liabilities of KRW 12.9 billion.

  5. 5

    On the pipeline side, the U.S. patent grant for AST-201 (reported on August 26, 2026) and the clinical collaboration with Merck (MSD) announced on April 15, 2026 are the key variables.

02

Business structure

CHOOLIP & SCIENCES (formerly Aptamer Sciences) is an aptamer-based biotech spun off from POSTECH in 2011, and it changed its corporate name on July 8, 2026.

Its marketed product is AptoDetect-Lung, a blood-based lung cancer early detection kit, and the company argues that using it as an adjunct test can raise accuracy by more than 20% over imaging, though this is the company's own claim.

On the therapeutics side, the core is the ApDC (Aptamer Drug Conjugate) platform, which attaches drugs to aptamers.

Its lead candidate AST-201 targets GPC3, couples the chemotherapy agent gemcitabine, is in a Phase 1 trial in Korea, and is being developed mainly for hepatocellular carcinoma and non-small cell lung cancer. The solid tumor candidate AST-203a targets Trop2 and was selected for a national new drug development program.

The third pillar is contract research (CRO) and bio-sample analysis, and on November 4, 2026 the company signed an MOU with a Korean CRO firm to jointly win Phase 1 and bioequivalence studies.

Partners include Merck (MSD), with which it signed a Keytruda combination trial and supply agreement in April 2026, and Curigin, with which it agreed in June 2025 to co-develop an aptamer-siRNA therapeutic.

In April 2026 it acquired 100% of U.S. pet food company CHOOLIP INC., and its articles of incorporation were also amended to add goods and distribution businesses.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩500M-₩2.1B−381.6%
2025Q4₩1.8B-₩1.9B−110.7%
2026Q1₩700M-₩1.5B−210.4%
2026Q2₩2.4B-₩3.1B−128.9%
2026Q3₩3.6B-₩1.6B−43.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩400M-₩8.3B-₩7.1B−2322.3%−24.3%56.2%
2023₩200M-₩12.2B-₩13.6B−5019.5%−87.9%110.2%
2024₩1.1B-₩7.1B-₩8.7B−651.2%−34.2%25.7%
2025₩3.5B-₩7.8B-₩8.6B−222.6%−30.5%45.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue fell from KRW 358 million in 2022 to KRW 243 million in 2023, a 32.1% decline, then rose 345.3% to KRW 1.08 billion in 2024 and 223.7% to KRW 3.5 billion in 2025, increasing in two consecutive years. Among 2022 to 2025, 2025 was the largest year and 2023 the smallest.

Operating losses were KRW 8.32 billion in 2022, KRW 12.2 billion in 2023, KRW 7.05 billion in 2024 and KRW 7.8 billion in 2025, so the company has been loss-making for four consecutive years. The loss widened in 2023, narrowed in 2024 and widened again in 2025.

The operating margin was -2,322.3% in 2022, -5,019.5% in 2023, -651.2% in 2024 and -222.6% in 2025, so the loss relative to revenue was smaller in 2025 than in 2024 as sales grew.

Attributable net losses were KRW 7.12 billion in 2022, KRW 13.6 billion in 2023, KRW 8.7 billion in 2024 and KRW 8.62 billion in 2025, and the net loss including non-controlling interests was recorded at the same yearly amounts.

Operating cash flow was negative in every year, at -KRW 5.78 billion in 2022, -KRW 11.2 billion in 2023, -KRW 5.9 billion in 2024 and -KRW 9.67 billion in 2025.

The debt ratio went from 110.2% in 2023 to 25.7% in 2024 and then 45.6% in 2025, and total equity of KRW 28.2 billion at the end of 2025 was entirely attributable to shareholders of the parent.

Quarterly revenue went from KRW 544 million in the third quarter of 2025 to KRW 1.76 billion in the fourth quarter, KRW 707 million in the first quarter of 2026, KRW 2.39 billion in the second quarter and KRW 3.64 billion in the third quarter.

Over the same period operating losses were KRW 2.08 billion, KRW 1.94 billion, KRW 1.49 billion, KRW 3.08 billion and KRW 1.59 billion, and attributable net losses were KRW 2.02 billion, KRW 3.01 billion, KRW 2.36 billion, KRW 4.26 billion and KRW 1.67 billion.

In the third quarter of 2026 revenue rose 568.5% year on year, and both the operating and attributable net losses narrowed from the prior quarter and the prior-year quarter.

However, in the second quarter of 2026 revenue increased while both losses widened, so revenue growth and loss reduction have not moved in the same direction every quarter. Attributable net losses for the last four quarters total KRW 11.3 billion.

According to a report in November 2026, the U.S. subsidiary CHOOLIP had revenue of about KRW 4.7 billion and an operating loss of about KRW 1 billion for April to September 2026. The public filing table alone cannot separate the contribution of the acquired subsidiary or the size of any one-off items.

05

Industry analysis

In lung cancer detection, the company argues that imaging suffers from high false-positive rates and positions its blood-based, non-invasive adjunct test as a differentiator.

Among domestic diagnostics peers are companies active in COVID-19 rapid test kits and infectious disease and genetic testing, and the company is a relatively early-stage business compared with several of them.

In therapeutics, antibody-drug conjugates such as Trodelvy and Enhertu have drawn attention for clinical results, and the company claims its aptamer-based conjugate offers superior specificity.

In Korea, LigaChem Biosciences and ABL Bio compete in the same oncology drug market with antibody-based ADC and bispecific platforms. Because CHOOLIP & SCIENCES uses an aptamer-drug conjugate approach, its technology differs from antibody-centered platforms.

The CRO market is served by several domestic contract organizations that split Phase 1 and preclinical work, and the company is pitching an integrated service that combines bio-sample analysis. On the demand side, global pharmaceutical R&D budgets and the number of drug candidates drive CRO volumes.

Securing a U.S. patent is viewed as strengthening intellectual property in a market where global technology deals are active. Measured by headcount, the company is mid-sized among domestic diagnostics peers, and the acquisition of a subsidiary has made its business structure more complex.

06

Outlook

The most direct near-term milestones the company has disclosed are the ongoing Phase 1 trial of AST-201 in Korea and the Keytruda combination trial with Merck. Merck supplies the Keytruda used in the combination trial and provides scientific collaboration during the study.

With the U.S. patent granted and announced on August 26, 2026, AST-201 now holds patent rights in Korea, China, Japan and the United States. The company says it will continue clinical development while seeking licensing and co-development deals with global pharmaceutical companies.

A follow-on candidate, AST-203a targeting Trop2, was selected for a national new drug development program. In CRO, the MOU with a Korean CRO firm aims to jointly win Phase 1 and bioequivalence studies and develop new bio-sample analysis methods.

On diversification, the company says it will keep its drug discovery and CRO businesses while adding healthcare and household goods distribution as another revenue base.

A Greened Economy report in November 2026 said the U.S. subsidiary's six-month sales were about 17% of the annual estimate used at acquisition, and that a goodwill balance of KRW 20.2 billion could require an impairment review at year-end closing.

The next periodic report is the 2026 annual report, and the goodwill treatment and whether quarterly sales keep growing will be the points to verify in it.

07

Valuation

PER
—
PBR
1.6×
ROE
-37.2%
EPS
-₩395
BPS
₩1,310
Dividend per share
₩0

The price-to-book ratio is above 1x, which means the shares carry a premium over net asset value. PER cannot be calculated because the company has posted net losses over the last four quarters, so it cannot be compared with peers on an earnings multiple.

The company pays no dividend, so there is little basis for comparing dividend yield with industry averages.

Since 2025 the company has issued convertible bonds and carried out several third-party share offerings, and in June 2026 its board approved a stock consolidation that changed the par value from KRW 500 to KRW 1,000.

This financing structure changes the share count and the basis for per-share value, so it should be read alongside any valuation. The valuation depends more on whether the AST-201 licensing materializes and how the operating loss narrows than on the share price itself.

Depending on the outcome of the goodwill impairment review, the equity base could change and so could the interpretation of the price-to-book ratio.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Quarterly revenue growth continues

Third-quarter 2026 revenue of KRW 3.64 billion rose 568.5% year on year and has grown for two straight quarters since the first quarter of 2026. One quarter of 2026 sales now exceeds the full-year 2025 revenue of KRW 3.5 billion, which supports the case for expansion. Quarterly sales have not risen in a straight line, so the next quarters need to be tracked.

Global partnership and patent for AST-201

A clinical collaboration and supply agreement with Merck (MSD), announced on April 15, 2026, supports a Keytruda combination trial. The U.S. patent grant for AST-201 announced on August 26, 2026 adds to patents already held in Korea, China and Japan. The company says it is seeking licensing and co-development opportunities.

Platform expansion alongside CRO

The ApDC platform is extending to follow-on candidates such as AST-203a, which targets Trop2 and was selected for a national new drug development program. A November 2026 MOU with a Korean CRO firm opens a path to jointly winning Phase 1 and bioequivalence studies. The CRO business could widen the revenue base alongside the drug pipeline.

09

Bear factors

Prolonged loss-making structure

The company has reported operating losses for four consecutive years from 2022 through 2025, and operating cash flow was -KRW 9.67 billion in 2025.

Operating and attributable net losses have continued for five straight quarters through the third quarter of 2026, and attributable net losses for the last four quarters total KRW 11.3 billion. Because losses remain large even as sales grow, the timing of a return to profit is hard to estimate.

Acquired subsidiary and goodwill burden

After acquiring 100% of U.S. pet food company CHOOLIP INC. in April 2026, the company booked goodwill of KRW 20.2 billion. A Greened Economy report said the subsidiary's six-month sales were about 17% of the annual estimate used at acquisition, with an operating loss of about KRW 1 billion. An impairment review at year-end could add to book losses.

Frequent financing and dilution

Financing since late 2025 has included a KRW 12 billion convertible bond and a KRW 10 billion third-party share offering in October 2025, a KRW 7 billion convertible bond in February 2026, and KRW 8 billion and KRW 12 billion third-party share offerings in April 2026.

Against total equity of KRW 28.2 billion at the end of 2025, this scale of financing adds to share-count dilution. A stock consolidation was also approved by the board in June 2026.

10

Risk factors

Clinical and licensing risk

AST-201 is in a Phase 1 trial in Korea, and the timing of indication expansion and any licensing deal has not been disclosed. A patent grant and a Merck collaboration do not by themselves mean commercialization. Disappointing clinical data could sharply change how the pipeline is valued.

Financial and dilution risk

Operating cash flow was negative in each year from 2022 through 2025. Conversion of convertible bonds and further share offerings could raise the share count and dilute existing shareholders. The result of the year-end goodwill review could change reported profit or loss significantly.

Trading and business focus risk

The stock was designated a KRX investment warning issue on October 13, 2026, was released on October 27 and moved to an investment caution designation, with re-designation tests running through November 9, 2026.

Some observers worry that adding goods and distribution could slow drug development, while the company says it will maintain its drug discovery and CRO businesses.

11

What to watch next

  1. End of December 2026

    Whether the KRW 20.2 billion goodwill tied to the U.S. subsidiary requires an impairment at year-end closing. The outcome would change 2026 profit or loss and equity.

  2. Early 2027 (typical timing for preliminary annual results)

    Preliminary fourth-quarter and full-year 2026 results. Investors can check whether the third-quarter revenue level of KRW 3.64 billion carried into the fourth quarter and whether the operating loss narrowed.

  3. End of March 2027 (statutory filing deadline)

    The 2026 annual report, the next periodic filing. It will confirm annual operating and attributable net losses, the treatment of goodwill and cash flow on a filed basis.

  4. Date not announced

    Progress of the Phase 1 trial of AST-201 in Korea, the start of the Merck combination trial and whether a licensing agreement is signed. Pipeline value is unlikely to reflect in reported results until these are confirmed.

12

Overall view

CHOOLIP & SCIENCES saw revenue grow in both 2024 and 2025, and third-quarter 2026 revenue of KRW 3.64 billion rose 568.5% year on year. On the other hand, operating losses have continued for four consecutive years from 2022 through 2025, and attributable net losses for the last four quarters total KRW 11.3 billion.

The operating margin improved to -222.6% in 2025 from 2024 but remains deeply negative. In the pipeline, the Merck combination trial and the U.S. patent grant for AST-201 are the largest advances, and whether a licensing deal will be signed has not been disclosed.

The U.S. subsidiary acquired in April 2026 and its KRW 20.2 billion goodwill could change reported results and equity depending on the year-end 2026 impairment review. Repeated capital raises also make share-count dilution a point to track.

The next checkpoints are the operating loss in the 2026 annual report and whether quarterly revenue is sustained.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. thevc.kr
  2. saramin.co.kr
  3. choolipscience.com
  4. google.com
  5. choolipscience.com
  6. m.news.nate.com
  7. edaily.co.kr
  8. topstarnews.net
  9. topstarnews.net
  10. view.asiae.co.kr
  11. newsprime.co.kr
  12. aptsci.com
  13. dealsite.co.kr
  14. greened.kr
  15. judal.co.kr
  16. en.fnnews.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis